Is etoricoxib safe for use in pregnant women?

Etoricoxib Safety in Pregnancy

Etoricoxib should be avoided during pregnancy, particularly after 28 weeks gestation, and should only be used with extreme caution in the first and second trimesters if absolutely necessary for disease control.

Key Recommendations

Timing-Based Risk Profile

First and Second Trimester (Before 28 weeks):

• Data for COX-2 inhibitors like etoricoxib are limited compared to non-selective NSAIDs 1
• If NSAIDs are absolutely necessary, short-term use (7-10 days maximum) in the lowest effective dose may be considered, but non-selective NSAIDs with short half-lives (e.g., ibuprofen) are strongly preferred over COX-2 inhibitors 1
• Early pregnancy NSAID exposure shows no clear evidence of increased miscarriage or teratogenicity risk, but this data is primarily for ibuprofen and diclofenac, not etoricoxib 1

Third Trimester (After 28 weeks gestation):

• All NSAIDs including etoricoxib must be discontinued after gestational week 28 1
• Risk of serious fetal complications increases dramatically in late pregnancy, including:
  • Premature closure of the ductus arteriosus 1, 2
  • Oligohydramnios (low amniotic fluid) 1
  • Delayed parturition and dystocia 2

Evidence Quality and Limitations

Critical Gap in Data

• The 2025 EULAR guidelines explicitly state that "data for COX-2 inhibitors are limited" when discussing pregnancy safety 1
• Most reassuring pregnancy data exists for ibuprofen, followed by diclofenac—not for selective COX-2 inhibitors like etoricoxib 1
• The FDA labeling provided references meloxicam (another COX-2 inhibitor) which is Category C before 30 weeks and Category D after 30 weeks, indicating known fetal risks 2

Mechanism of Harm

• NSAIDs work by inhibiting prostaglandin synthesis, which is essential for:
  • Maintaining patency of the ductus arteriosus in the fetus 1
  • Normal amniotic fluid production 1
  • Ovulation (can cause luteinized unruptured follicle syndrome if used periovulationally) 1

Clinical Algorithm

Step 1: Determine gestational age

• If ≥28 weeks: Do not use etoricoxib under any circumstances 1

Step 2: If <28 weeks and pain control is essential:

• First choice: Non-pharmacologic interventions 3
• Second choice: Acetaminophen (though recent safety concerns warrant judicious use) 3
• Third choice: Short-acting non-selective NSAID (ibuprofen preferred) for ≤7-10 days maximum 1
• Avoid etoricoxib due to limited pregnancy data compared to alternatives 1

Step 3: If patient is trying to conceive:

• Discontinue etoricoxib as continuous periovulatory NSAID exposure can reduce fertility 1

Important Caveats

• The single study showing etoricoxib use for first-trimester termination of pregnancy 4 does not establish safety for ongoing pregnancy, as the pregnancy was intentionally terminated
• Women with rheumatologic conditions requiring anti-inflammatory therapy should transition to pregnancy-compatible alternatives (hydroxychloroquine, sulfasalazine, azathioprine, low-dose prednisone ≤5mg/day) well before conception 1, 5
• If inadvertent exposure occurs in early pregnancy, counsel the patient but do not automatically recommend termination, as early NSAID exposure data (primarily for non-selective NSAIDs) does not show clear teratogenicity 1